Cytogenetic abnormalities commonly associated with acute lymphoblastic leukemia (ALL) are detected by fluorescence in situ hybridization (FISH). Probes for TCF3/PBX1 t(1;19), BCR/ABL1-ASS1 t(9;22), CDKN2A (9p21.3), KMT2A (MLL)(11q23.3), ETV6/RUNX1 t(12;21)/(iAMP21), IGH (14q32.3), TP53 (17p13.1) are included in the ALL FISH Profile.
B-NHL FISH Profile (Enriched)
B-cell Non-Hodgkin Lymphomas (NHL), Burkitt Lymphoma (BL), Cytogenetics, Diffuse Large B-cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), FISH, Follicular Lymphoma (FL), Hematologic Diseases, Lymphoplasmacytic Lymphoma (LPL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL)Cytogenetic abnormalities commonly associated with high-grade B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), IRF4-DUSP22 (6p25.3), MYC (8q24.21), IGH/BCL2 t(14;18)) are included in the B-NHL High-Grade FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.
Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), IGH (14q32.3), and TP53 (17p13.1) are included in the Myeloma Reflex FISH Profile (Enriched). If IGH positive, Genoptix will reflex to IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16) and IGH/MAFB t(14;20). Plasma cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD138 antibody.
Cytogenetic abnormalities commonly associated with acute lymphoblastic leukemia (ALL) are detected by fluorescence in situ hybridization (FISH). Probes PDGFRb (5q32), BCR/ABL1-ASS1 t(9;22), JAK2 (9p24.1), EPOR (19p13.2) and CRLF2 (Xp22.33/Yp11.32) are included in the ALL FISH (Ph-like) Profile.
Cytogenetic abnormalities commonly associated with pediatric acute lymphoblastic leukemia (ALL) are detected by fluorescence in situ hybridization (FISH). Probes for Cen 4, Cen 10 (+4/+10), BCR/ABL1-ASS1 t(9;22), KMT2A (MLL)(11q23.3), ETV6/RUNX1 t(12;21)/(iAMP21) and IGH (14q32.3) are included for pediatric cases of ALL.
Consultation by a Genoptix Hematopathologist on previously diagnosed cases. We require appropriate clinical data and slides, as well as the most recent morphology report and laboratory test results.
When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.
The client’s pathologist must provide the cytogenetics report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, blood or bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), and molecular tests as medically necessary.
The client’s pathologist must provide the flow cytometry report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
The client’s pathologist must provide the morphology report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
CONTACT US
Genoptix, a NeoGenomics Company
2131 Faraday Ave
Carlsbad, CA 92008
Phone: +1.760.268.6200
Fax: +1.760.268.6201
Client Services
Phone: +1.800.755.1605
Fax: +1.888.755.1604
Email: clientservices@genoptix.com
Medical Director: Derek Lyle, MD
Recent News
NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
